Arrayed CRISPR screening for phenotypic discovery at the MRC-AstraZeneca-University of Cambridge Joint Functional Genomics Screening Laboratory (FGSL)
The FGSL aims to form collaborations to advance our understanding of development and disease mechanism through functional interrogation of the genome at scale.
Bringing Oncology Intelligence to Early Drug Development With AI-Powered Response Predictions
In this webinar, learn how AI technologies can accelerate oncology drug discovery and enhance the success of anti-cancer agents.
Next-Generation Safety Assessment Tools for Advancing In Vivo to In Vitro Translation
In this webinar, Dr. Louis Scott discusses the morph_ONE™ assay, a novel tool for in vitro safety assessment in drug development.
#ExpertAnswers: Jack Vanden Heuvel on Prediction Drug-Drug Interactions Early
Dr. Jack Vanden Heuvel from Penn State University and INDIGO Biosciences answers questions from a recent webinar where he discusses [...]
How to Better Predict Potential Drug Interactions Early in the Discovery Process
Dr. Jack Vanden Heuvel answers questions about the prediction of drug-drug interactions using in vitro assays and gene expression studies.
How to Better Predict Potential Drug Interactions Early in the Discovery Process
Join our webinar to discover effective strategies for early prediction of drug-drug interactions using in-vitro assays and gene expression studies.
Advancing Disease Modeling for Drug Discovery by Modulating iPSCs with CRISPR and Neuronal Differentiation
Explore applications of CRISPR and iPSCs in disease modeling and drug discovery in our upcoming webinar with Synthego and BrainXell.
#ExpertAnswers: Jack Vanden Heuvel on Nuclear Receptor Profiling
Dr. Jack Vanden Heuvel from Penn State University answers questions from a recent webinar discussing the use of cell-based reporter [...]
Save Time and Money When Prioritizing Drug Candidates: Using Cell-Based Reporter Assays for Nuclear Receptor Profiling
Dr. Jack Vanden Heuvel discusses the use of cell-based reporter assays for nuclear receptor profiling to efficiently prioritize drug candidates and minimize off-target effects.
